Oramed Pharmaceuticals (ORMP) Stock Price, News & Analysis

Company Overview

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) is a biopharmaceutical company focused on developing oral formulations of drugs that are typically administered by injection. The company’s proprietary Protein Oral Delivery (POD™) technology is designed to protect therapeutic proteins from degradation in the digestive system and facilitate their absorption through the gastrointestinal tract.

Oramed’s development programs have primarily focused on oral insulin, including its investigational ORMD-0801 product candidate for the treatment of diabetes. The company has also explored oral formulations of other peptide-based therapies, including GLP-1-related treatments. These products remain investigational and are subject to clinical testing and regulatory approval; they are not established commercial therapies.

Founded in 2006, Oramed operates with ties to Israel and the United States. Nadav Kidron has served as the company’s chief executive officer, while Professor Miriam Kidron has been associated with its scientific and research activities. The company’s work is centered on advancing its oral drug-delivery platform and partnering or pursuing development opportunities for therapies that could offer alternatives to injectable medicines.

Key Stats

• Today's Range: $4.05 to $4.17
• 50-Day Range: $4.06 to $5.34
• 52-Week Range: $2.09 to $5.47
• Volume: 97,228 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: 1.01
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

Oramed Pharmaceuticals Stock Analysis - MarketRank™

Oramed Pharmaceuticals scored higher than 30% of companies evaluated by MarketBeat, and ranked 671st out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.7 / 5
• Analyst Rating: Buy

Consensus Rating

Oramed Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Oramed Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Oramed Pharmaceuticals is 1.01, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.57.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oramed Pharmaceuticals is 1.01, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.35.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.40% of the float of Oramed Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Oramed Pharmaceuticals has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Oramed Pharmaceuticals has recently increased by 1.23%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oramed Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Oramed Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 1.23

News Sentiment

Oramed Pharmaceuticals has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Oramed Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

Only 2 people have searched for ORMP on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Oramed Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $225,500.00 in company stock.

Percentage Held by Insiders

20.77% of the stock of Oramed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

12.73% of the stock of Oramed Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/28/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ORMP
• CIK: 1176309
• Web: www.oramed.com
• Phone: (844) 967-2633
• Fax: 972-2566-0004
• Employees: 13
• Year Founded: 2006

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 1.01
• Forward P/E Ratio: 2.83
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: 32,957,000
• Market Cap: N/A
• Optionable: Optionable
• Beta: N/A